The Latest
Roche’s Collaborator MediLink Announces Phase III Data For Tam-Peli Showing Significantly Improved Overall Survival In Chinese Patient Population With Relapsed Small-cell Lung Cancer
MediLink reports significant overall survival improvement in Chinese relapsed small-cell lung cancer patients using Tam-Peli, a Roche collaborator’s therapy, based on Phase III results.